Top 10 Poster Presentations
Discover the latest research at our Top 10 Poster Presentations. Each presenter will have 3 minutes to present and 2 minutes for Q&A, offering a quick yet insightful look at their studies.
Vote for the Best Poster via the ICLE 2026 mobile app and help select the top research! The winners will be announced during the closing session.
Date: 16 July
Time: 12:40 β 13:50
Location: Exhibition Hall
Moderator:
Marion Subklewe
LMU,
Germany
Katia Palmisano
IRCCS San Raffaele Scientific Institute
Italy
COMBINATORIAL STRATEGY FOR IMPROVED CDH17 CAR T CELL THERAPY OF LIVER METASTASES FROM COLORECTAL CANCER
π 12:40 β 12:45
Christian Pellegrino
Philochem AG
Switzerland
IMPROVED CAR T-CELL EFFECTIVENESS AGAINST SOLID TUMORS BY TUMOR-RESTRICTED CYTOKINE DELIVERY VIA IMMUNOCYTOKINESπ 12:45 β 12:50
Kathrin Gabriel
LMU Klinikum
Germany
A MODULAR CAR T CELL PLATFORM FOR TARGETED IMMUNOTHERAPY OF ACUTE MYELOID LEUKEMIA
π 12:50 β 12:55
Elise Sylvander
BOKU Vienna
Austria
CAFFEINE-REGULATED MOLECULAR SWITCHES FOR FUNCTIONAL CONTROL OF CAR T CELLS
π 12:55 β 13:00
Emilia Vigolo
Veneto Institute of Oncology – IOV
Italy
BREAKING THE MATRIX BARRIER: ENHANCING CAR-T CELL ACCESS TO SOLID TUMORS
π 13:00 β 13:05
Kersten M. Heyer
Technical University of Munich
Germany
ULTRA-DEEP MURINE EPITOPE-SPECIFIC TCR LIBRARIES IDENTIFY DISPARATE CONTRIBUTIONS OF T CELL RECEPTOR CHAINS AS A COMMON MODE OF FUNCTIONAL EPITOPE RECOGNITION
π 13:05 β 13:10
Chiara Chiavelli
University of Modena and Reggio Emilia
Italy
ANTI-GD2 CAR T CELLS EFFICIENTLY TARGET EWINGβS SARCOMA
π 13:10 β 13:15
Pinar Ataca Atilla
University of Miami
United States of America
TROGOCYTOSIS AND THE PARADOXIMAL IMPACT OF GAMMA SECRETASE INHIBITION ON BCMA CAR T CELLS
π 13:15 β 13:20
Koramit Suppipat
Chulalongkorn University
Thailand
LOCOREGIONAL IL-7RΞβENHANCED B7-H3 CAR T CELLS (CMD03) IN PEDIATRIC DIPG: PRELIMINARY RESULTS FROM A PHASE I DOSE-ESCALATION TRIAL
π 13:20 β 13:25
Maria Chiara Maffia
San Raffaele Scientific Institute
Italy
SINGLE-CELL PROFILING GUIDES A DISEASE-TAILORED TCR-BASED IMMUNOTHERAPY FOR EPITHELIAL OVARIAN CANCER
π 13:25 β 13:30